CRISPR, tomato

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...
Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...
Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...
In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...
EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...
In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...